IDEAS home Printed from https://ideas.repec.org/a/eee/csdana/v206y2025ics0167947325000064.html

A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients

Author

Listed:
  • Bilancia, Massimo
  • Solimando, Antonio Giovanni
  • Manca, Fabio
  • Vacca, Angelo
  • Ria, Roberto

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells, originating from B lymphocytes and accumulating within the bone marrow. The prevalence of MM has increased in industrialized countries, representing 1-1.8% of all cancers and 15% of hematologic malignancies. Immunotherapy has broadened therapeutic options for MM, offering treatments with generally improved efficacy and reduced toxicity compared to conventional therapies. Daratumumab, a monoclonal antibody recently granted regulatory approval, exemplifies this advancement, demonstrating improved patient outcomes. However, the substantial cost of daratumumab has significantly increased per-patient treatment expenditures. Consequently, the economic burden associated with this new class of therapies warrants careful evaluation of their cost-effectiveness. To address this, a six-state non-stationary Markov model was developed for cost-effectiveness analysis of immunotherapy in newly diagnosed MM patients and, more broadly, in the oncohematological patient population. This model aims to provide healthcare professionals and policymakers with actionable insights into cost-effective interventions, supporting informed decisions regarding optimal treatment strategies.

Suggested Citation

  • Bilancia, Massimo & Solimando, Antonio Giovanni & Manca, Fabio & Vacca, Angelo & Ria, Roberto, 2025. "A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients," Computational Statistics & Data Analysis, Elsevier, vol. 206(C).
    • Handle: RePEc:eee:csdana:v:206:y:2025:i:c:s0167947325000064
    DOI: 10.1016/j.csda.2025.108130
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0167947325000064
    Download Restriction: Full text for ScienceDirect subscribers only.
    File URL: https://libkey.io/10.1016/j.csda.2025.108130?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 3-20, January.
    2. Rachael Fleurence & Christopher Hollenbeak, 2007. "Rates and Probabilities in Economic Modelling," PharmacoEconomics, Springer, vol. 25(1), pages 3-6, January.
    3. Jackson, Christopher, 2016. "flexsurv: A Platform for Parametric Survival Modeling in R," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 70(i08).
    4. Vakaramoko Diaby & Georges Adunlin & Alberto Montero, 2014. "Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial," PharmacoEconomics, Springer, vol. 32(2), pages 101-108, February.
    5. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    6. Fernando Alarid-Escudero & Eline M. Krijkamp & Petros Pechlivanoglou & Hawre Jalal & Szu-Yu Zoe Kao & Alan Yang & Eva A. Enns, 2019. "A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling," PharmacoEconomics, Springer, vol. 37(11), pages 1329-1339, November.
    7. Risha Gidwani & Louise B. Russell, 2020. "Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1153-1164, November.
    8. Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson, 2018. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models," PharmacoEconomics, Springer, vol. 36(12), pages 1421-1426, December.
    9. Elamin Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    10. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.
    11. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers," PharmacoEconomics, Springer, vol. 34(1), pages 13-22, January.
    12. Eline M. Krijkamp & Fernando Alarid-Escudero & Eva A. Enns & Petros Pechlivanoglou & M.G. Myriam Hunink & Alan Yang & Hawre J. Jalal, 2020. "A Multidimensional Array Representation of State-Transition Model Dynamics," Medical Decision Making, , vol. 40(2), pages 242-248, February.
    13. David M. J. Naimark & Michelle Bott & Murray Krahn, 2008. "The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches," Medical Decision Making, , vol. 28(5), pages 706-712, September.
    14. Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 21-41, January.
    15. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    16. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods," Medical Decision Making, , vol. 36(1), pages 115-131, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden, 2021. "Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals," PharmacoEconomics, Springer, vol. 39(8), pages 869-878, August.
    2. del Campo, Cristina & Bai, Jiaru & Keller, L. Robin, 2025. "Modeling cost-effectiveness analysis of treatment sequencing," Socio-Economic Planning Sciences, Elsevier, vol. 99(C).
    3. Xiaomin Wan & Liubao Peng & Yuanjian Li, 2015. "A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-21, March.
    4. Jean Martial Kouame & Carole Siani & Christian Kouakou & Soualio Gnanou & Simon LaRue & Jason Robert Guertin, 2025. "Modeling in R: a practical application using a cost-effectiveness analysis," Health Economics Review, Springer, vol. 15(1), pages 1-11, December.
    5. Rashidah T Uthman & Andrew J Sutton & Louise J Jackson & Olalekan A Uthman, 2018. "Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-15, January.
    6. Yixin Xu & Elsa M. R. Marques & Nicky J. Welton & Linda P. Hunt & Michael Whitehouse & Ashley W. Blom & Andrew D. Beswick & Howard H. Z. Thom, 2026. "Spectrum of Models for Assessing the Cost Effectiveness of Total Knee Replacement Implants: A Comparison of Discrete-Time Cohort Markov and Continuous-Time Individual-Level Multistate Models," PharmacoEconomics, Springer, vol. 44(4), pages 477-494, April.
    7. Matthijs M. Versteegh & Simone A. Huygens & Inigo Bermejo & Sabine Grimm & Marieke Pierik & Tessa Römkens & Fiona Schaik & Peter Wahab, 2025. "Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease," PharmacoEconomics, Springer, vol. 43(12), pages 1405-1417, December.
    8. Kangho Suh & Brian J. Cole & Andreas Gomoll & Seung-Mi Lee & Hangseok Choi & Chul-Won Ha & Hong Chul Lim & Myung Ku Kim & Gwi-Yeom Ha & Dong-Churl Suh, 2023. "Cost Effectiveness of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Patients with Knee Osteoarthritis," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 141-152, January.
    9. Enoch Yi-Tung Chen & Paul W. Dickman & Mark S. Clements, 2025. "A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment," PharmacoEconomics, Springer, vol. 43(3), pages 297-310, March.
    10. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    11. Agi McFarland & Sarkis Manoukian & Helen Mason & Jacqui Reilly, 2026. "A Cost–Utility Analysis of Surgical Site Infection Prevention: Broadening the Scope," Applied Health Economics and Health Policy, Springer, vol. 24(2), pages 421-435, March.
    12. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    13. Carmen María Yago & Francisco Javier Díez, 2023. "DESnets: A Graphical Representation for Discrete Event Simulation and Cost-Effectiveness Analysis," Mathematics, MDPI, vol. 11(7), pages 1-24, March.
    14. Svenn Alexander Hansen & Eline Aas & Oddvar Solli, 2020. "A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 73-84, February.
    15. Charlotte C Hamel & Marcus P L M Snijders & Sjors F P J Coppus & Frank P H A Vandenbussche & Didi D M Braat & Eddy M M Adang, 2022. "Economic evaluation of a randomized controlled trial comparing mifepristone and misoprostol with misoprostol alone in the treatment of early pregnancy loss," PLOS ONE, Public Library of Science, vol. 17(2), pages 1-13, February.
    16. Massimo Bilancia & Giuseppe Pasculli & Danilo Di Bona, 2020. "A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-33, May.
    17. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    18. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    19. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    20. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:csdana:v:206:y:2025:i:c:s0167947325000064. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/csda .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.